Business Wire

Boies Schiller Flexner LLP to Appeal U.S. Court’s Decision on Behalf of Kingstown Capital Against Radovan Vitek and Others

9.10.2020 16:32:00 EEST | Business Wire | Press release

Share

U.S.-based asset manager, Kingstown Capital Management L.P. and Investhold Ltd. (“the Plaintiffs”) today announced its appeal against the decision of the U.S. District Court for the Southern District of New York to dismiss a Racketeer Influenced and Corrupt Organizations Act (“RICO”) lawsuit filed in April 2019 against Czech oligarch, Radovan Vitek, and other co-conspirators.

In a decision of first instance, the court ruled that it is more appropriate for the lawsuit to be pursued in a European jurisdiction as opposed to in the United States. The court did not take into consideration the merits or legitimacy of the plaintiffs’ claims, at the heart of which allege a long-running scheme on the part of Vitek, a Forbes billionaire with business interests throughout Europe, and his co-conspirators to defraud and engage in other criminal conduct.

The claim details a series of racketeering activities, including wire fraud, mail fraud, money laundering and other crimes, enabling Vitek to make billions of dollars at the expense of the Plaintiffs. Detailed in the complaint also are the efforts of Vitek to covertly grow his scheme into an extensive international conspiracy over a period of a decade.

Matthew L Schwartz, a partner at Boies Schiller Flexner LLP and counsel to the plaintiffs, said: “Our clients are committed to seeing justice done and we are fully confident in the merits of the case, which were not dealt with in the court’s decision. We maintain that the U.S. District Court for the Southern District of New York is an appropriate forum for these claims to be heard and are appealing on this basis.”

The complaint states that in 2017, the Luxembourg financial regulator, Commission de Surveillance du Secteur Financier (“CSSF”), launched an investigation into Vitek, Jean-Francois Ott, and CPI Property Group and found that “Vitek and Ott had ‘acted in covert concert,’ secretly controlled real estate company ORCO, and therefore violated Luxembourg and European law.” As a result the CSSF fined Vitek and Ott for market manipulation infringements.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Edward Evans
Director of Communications
BOIES SCHILLER FLEXNER LLP
212-446-2354
eevans@bsfllp.com
www.bsfllp.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Xsolla to Meet With Mobile Game Developers and Publishers at Pocket Gamer Connects Barcelona 202611.6.2026 16:00:00 EEST | Press release

Xsolla, a leading global video game commerce company, today announced its participation in Pocket Gamer Connects (PGC) Barcelona 2026, taking place June 15-16 at the Hyatt Regency Barcelona in Barcelona, Spain. Xsolla will be on the ground for meetings with mobile game developers, publishers, and strategic partners, bringing its direct-to-consumer commerce infrastructure to one of the most deal-focused events in the European games calendar. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260611487209/en/ Graphic: Xsolla Now in its second year, PGC Barcelona has quickly established itself as a destination conference for mobile game businesses, drawing more than 1,000 attendees from over 47 countries and facilitating thousands of structured business meetings through its dedicated matchmaking platform. Barcelona itself has become one of Europe's most significant gaming cities, home to studios including Scopely, King, Rovio, Band

Onera Will Showcase Its Onera hPSG® Solution at the SLEEP 2026 Conference June 14-17, 2026 in Baltimore, MD, USA.11.6.2026 16:00:00 EEST | Press release

Onera Health, a leader in transforming sleep medicine, announces that its end-to-end home polysomnography solution, the Onera hPSG® solution, will be prominently featured in multiple scientific presentations at the forthcoming SLEEP 2026 conference. The medtech company will showcase this innovative solution at booth #600 during the largest annual sleep medicine conference, which brings together leading experts and innovators in the field. Furthermore, in anticipation of new CPT codes, Onera Health will host an educational symposium on Scaling PSG for the Next Decade: Expanding Utilization of High-Complexity Home Testingon Monday, June 15. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260611302332/en/ Onera hPSG® – Bringing PSG Home. “We are excited to see our Onera hPSG® solution highlighted at this important meeting in three different presentations and an educational seminar. Onera hPSG® is positioned to be an integral par

IQM Quantum Computer Goes Live at Supercomputing Center CINECA in Italy, Boosting National Compute Infrastructure and Research11.6.2026 15:50:00 EEST | Press release

The Italian Research Centre on High Performance Computing, Big Data, and Quantum Computing (ICSC) today inaugurated the IQM Radiance 54 quantum computer at CINECA, one of Europe's leading supercomputing centers, enabling advanced applications in optimization, simulation, and machine learning. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260611898215/en/ The moment Italy's second IQM quantum computer went live at CINECA in Bologna. IQM has previously announced its ongoing business combination with Real Asset Acquisition Corp (Nasdaq: RAAQ), which will result in IQM becoming a public company in mid-2026. The installation, located at the CINECA headquarters in the DAMA Tecnopolo in Bologna, represents not just technological progress but a strategic Italian asset providing concrete tools for the scientific community and businesses to foster innovation, accelerate research, and transform knowledge into high-impact applications.

Wyss Geneva Steps Into Its Next Chapter11.6.2026 14:33:00 EEST | Press release

The Wyss Center for Bio and Neuroengineering in Geneva is pleased to announce the appointment of Dr. Tracy Laabs as Director, effective July 1st 2026. Dr. Laabs succeeds Prof. Dr. Erwin Böttinger, who leaves behind a fundamentally transformed organization: one that no longer just pursues breakthrough science but systematically turns it into ventures that reach patients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260611328520/en/ Dr. Tracy Laabs, incoming Director, Wyss Center Geneva Since joining the Wyss Center as Director in April 2023, Prof. Böttinger brought a bold vision: to evolve the Center from a portfolio of promising projects into a disciplined engine for venture creation. Under his leadership, the Center spun off six companies in two years (including ABILITY Neurotech SA and Clee Medical SA in 2025) while simultaneously building a robust pipeline of next-generation programs in AI-guided neuromodulation and min

BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit11.6.2026 14:24:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced the presentation of a large Phase 3 dataset in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) aged 80 and older, showing sustained benefit with BRUKINSA after nearly 6.5 years of follow-up, reinforcing its role as the foundational BTK inhibitor. BRUKINSA is the only BTK inhibitor to demonstrate superior efficacy vs. ibrutinib in a Phase 3 trial.1 These data, one of the largest datasets of older patients with treatment-naive CLL, will be presented at the 2026 European Hematology Association (EHA) Congress in Stockholm, Sweden. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: "While the median age of diagnosis for CLL is 70 and the average age of treatment initiation is 75, many pivotal trials still underrepresent the patients that physicians most often see in practice. These data show that the durable benefit of

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye